Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Health and Social Care Act

- PMLiVE

NICE backs Eisai’s Halaven for breast cancer

Reverses 2012 rejection due to new data and patient access discount

- PMLiVE

NICE set to reject Merck’s Erbitux for head and neck cancer

Draft guidance rules the treatment does not provide value for money

Communicating with payers to improve patient access

A transforming NHS brings with it many opportunities. Working with payers to put patients at the heart of everything while reducing costs is fundamental to success.

- PMLiVE

UK to cut wait to innovative treatments by four years

Proposals in the Accelerated Access Review aim to speed up access to innovation

- PMLiVE

NHS marks its Twitter debut with story-sharing initiative

Three-month project will see a patient or staff member take over the new account

- PMLiVE

Regional NHS pulmonary rehabilitation video campaign launched

Aims to boost referral rates among GPs in the north east of England

- PMLiVE

The UK’s new Cancer Drugs Fund

"Clearer, faster decision-making" promised

UK to establish a digital academy for healthcare professionals

NHS technology plans will also see 12 trusts act as digitisation pioneers

- PMLiVE

NHS promotes person-centred care in new dementia film

Highlights the importance of enabling people to live well with the condition

- PMLiVE

NHS goes global with ‘Missing Type’ blood donor campaign

High profile brand partnership has already involved the likes of Microsoft, Waterstones and the RAF

- PMLiVE

Portrait exhibition raises refugee healthcare profile

Doctors of the World opens gallery to mark 10-year anniversary of its London clinic

Novartis Gehry Building

NICE backs Cosentyx for ankylosing spondylitis

The immunotherapy is on course to be “one of the most successful launches in Novartis history”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links